AngioGenex, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by ARONSTEIN MICHAEL, was filed 04 Feb 2019.
AngioGenex, Inc.: what insiders have been doing
AngioGenex, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for AngioGenex, Inc. The previous disclosure was published on 4 February 2019.
The full history, which starts in 2006, counts 2 purchases against no sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2018FY ended December 2018 · cache
- 1,000,000 shares@ US$0.20100.0% of flowCOMMON STOCKSEC:0001469709-19-000006:0Canonical exit: 15 Apr 2019 (T+90)
- 15,000 shares@ US$5,000.00Common StockSEC:0001144204-08-053036:0Canonical exit: 14 Dec 2008 (T+90)
- 10,000,000 shares0Common, par value $0.001SEC:0001275126-06-000001:0
3 of 3 declarations
About AngioGenex, Inc.
AngioGenex, Inc. is a company focused on developing innovative treatments for vascular diseases and cancer. It is listed on the XNAS market.
